palopegteriparatide
Selected indexed studies
- Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. (Adv Ther, 2024) [PMID:38691316]
- PTH Substitution Therapy for Chronic Hypoparathyroidism: PTH 1-84 and Palopegteriparatide. (Curr Osteoporos Rep, 2025) [PMID:39987371]
- Palopegteriparatide. (Am J Health Syst Pharm, 2025) [PMID:39437769]
_Worker-drafted node — pending editorial review._
Connections
palopegteriparatide is a side effect of
Sources
- Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. (2024) pubmed
- PTH Substitution Therapy for Chronic Hypoparathyroidism: PTH 1-84 and Palopegteriparatide. (2025) pubmed
- Palopegteriparatide. (2025) pubmed
- Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. (2025) pubmed
- Palopegteriparatide (Yorvipath) for hypoparathyroidism. (2025) pubmed
- Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial. (2023) pubmed
- Hypoparathyroidism: diagnosis, management and emerging therapies. (2025) pubmed
- Rebound Effect Following the Discontinuation of Palopegteriparatide. (2025) pubmed
- Teriparatide. (2006) pubmed
- Advances in Parathyroid Hormone-based medicines. (2025) pubmed